GlassScriptPhysician profile
Joseph Mardelli
NPI 1376543538
$2,265.10
in general payments reported to CMS, 2019-2025
26 companies · $430 in 2025
The $430 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $107 · 2021: $94.27 · 2022: $517 · 2023: $576 · 2024: $184 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.54 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $332.34 | 2019-2025 | |
| Zoll Medical Corporation | $250.00 | 2023 | |
| Harmony Biosciences LLC | $224.50 | 2020-2025 | Wakix |
| Becton, Dickinson and Company | $204.17 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $193.15 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $182.33 | 2019-2025 | Nucala, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $129.16 | 2023-2025 | Inspire |
| Sunovion Pharmaceuticals INC. | $85.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.15 | 2019-2023 | Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $69.23 | 2022-2025 | Dupixent |
| Ethicon INC. | $62.87 | 2024 | Monarch Platform |
| Resmed Corp | $58.18 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.22 | 2023-2024 | Glassia |
| Medtronic, INC. | $45.00 | 2022 | |
| Mylan Specialty L.P. | $40.77 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $39.79 | 2023-2025 | Sunosi |
| Philips North America LLC | $33.42 | 2019-2020 | |
| Insmed, INC. | $30.34 | 2019-2025 | Arikayce |
| Electromed, INC. | $30.26 | 2019-2022 | |
| Lilly USA, LLC | $29.23 | 2025 | Zepbound |
| Grifols USA, LLC | $26.54 | 2019 | |
| Genzyme Corporation | $21.12 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.09 | 2020 | |
| Tactile Systems Technology INC | $13.32 | 2022 | |
| Merck Sharp & Dohme LLC | $13.28 | 2024 | |
| Janssen Pharmaceuticals, INC | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mardelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.